Tag: LEVI

Kicking Off a Fresh Trading Week

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares (ETF) GUSH

On Wednesday morning, we tagged GUSH for observation, and after just a few sessions , it came up off Wednesday’s low at 20.37 fairly convincingly.

On Thursday, this fund ran to a new high of 29.25, which marked a two-session upswing totaling a relatively modest yet respectable 44% increase. We will continue to monitor GUSH, which was a $500/share fund just six weeks ago.

Levi Strauss & Co. LEVI – Options Update 

We signaled a range of LEVI calls last week, also on Wednesday, in the LEVI 04/17 $12-13 Calls, and saw some solid gains from those ideas in the final two days of the short week. Both contract sets experienced multi-bag gains as follows:

LEVI 04/17 $12-13 Calls
$12:.80-2.55 (+150%)
$13: .30-1.70 (+283%)

These plays expire on Friday, so we’ll leave them on the radar to see what they have in store for this fresh trading week.
______

Fresh Options Ideas:
SRC 05/15 $35-40 Calls
GILD Weekly $74.50-76 Calls 

HUGE Options Success on Short Week


Johnson & Johnson JNJ 

Our coverage of JNJ options continues today as we close out this short trading week. We have been hot on the trail of this chain since last Monday, adjusting our ideas as we go, and have landed on the JNJ Weekly $140-142 Calls. Those contract sets have set new highs for us multiple times already, and yesterday’s session was no exception.

The markets went on another tear, going majorly green across the board, and that produced the following ranges and potential intraday mega-gains: 

JNJ Weekly $140-142 Calls
$140: .55-4.40 (+700%)
$141: .37-3.35 (+805%)
$142: .25-2.68 (+972%)
_____

SPDR S&P500 (ETF) SPY – We would also like to update on the SPY calls we made this Monday morning.  We signaled the Weekly $258-260 Calls, and those have made some really nice headway as well, providing for the following gain opportunities:

Weekly $258-260 Calls 
$258: 4.07-16.85 (+314%)
$259: 3.61-15.86 (+339%)
$260: 3.11-15.13 (+386%)

We will go ahead and roll up to track the SPY Weekly $274-275 Calls into the close today. 

More Options Updates 

We also generated a pair of fresh ideas for yesterday’s morning report based off of earnings, and both of those played fairly well on the day.

LEVI 04/17 $12-13 Calls
$12:.80-2.00 (+150%)
$13: .30-1.15 (+283%)

SGH 04/17 $22.50-25 Calls 
$22.50: 2.05-3.21 (+52%)
$25: .65-1.85 (+185%)

Extended  Watchlist:
USWS, TLSA, TBLT, NLS, ZSAN, RIG, MFSO

Added Note: 

We have been getting an inordinate amount of new subscribers in recent weeks, with more people at home, and still more who are simply trying to maximize their trading opportunities during this difficult time. Regardless of your reasoning for joining our ranks, we would like to offer you a big ‘Welcome to the Family’, and encourage all newcomers to take advantage of our live daily traders chats on Skype (Send contact request to “stocksumo”) 

DECN Recap & More

Decision Diagnostics, Corp. DECN 

We began tracking DECN just under three weeks ago, back on the morning of March 19th. The stock caught our attention after announcing that it was working on a rapid-result COVID-19 test. Subsequent to that point in time, it was trading for as little as .056/share.

Yesterday, following another tag in our extended watchlist, and as an update on the company’s coronavirus test was provided (excerpt and link below), the stock reached some very impressive new highs. It’s not the first coronavirus related play we’ve scored on, and it won’t be the last.

DECN ran 216% intraday from .125 to a new high of .395. From our initially observed low from the week before last, the stock has now exhibited an upswing of 605%

Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc.  …announces today that the company has received the Pre-EUA Acknowledgement letter from the U.S. FDA for device (serial number) PEUA200232, GenViro Covid-19 Screening Kit. This grant by the FDA is a major milestone in our GenViro!™ Covid-19 test kit development (>>View Full PR)

Johnson & Johnson JNJ – Recap

After seeing success with a number of different targets within the JNJ chain over the past week and change, we rolled our potential strike prices up to the JNJ Weekly $140-142 Calls yesterday morning.

Being one of the lead candidates for potentially developing an effective COVID-19 vaccine, it puts JNJ in a somewhat unique position, as experts have repeatedly stated that the world cannot begin to fully recover until a viable vaccine is being widely administered sometime next year.

Our move to the $140-142 Calls proved prudent yesterday, as early activity provided the following intraday opportunities: 

JNJ Weekly $140-142 Calls
$140: .89-2.88 (+224%)
$141: .62-2.31 (+273%)
$142: .43-1.67 (+288%)
_____

Fresh Ideas:
LEVI 04/17 $12-13 Calls
SGH 04/17 $22.50-25 Calls 

Extended  Watchlist:
BIEI, MBRX PINS, BNGO, SONN, EFC, NYMT